According to the news of the State Drug Administration on January 11, according to Article 83 of the Drug Administration Law of the People's Republic of China and other relevant provisions, the State Drug Administration organized a post-market evaluation of Libizhi injection. After evaluation, the State Drug Administration decided to stop the production, sale and use of Lianbizhi injection in China from now on, and cancel the drug registration certificate. The products that have been put on the market shall be recalled by the holder of the drug marketing authorization, and the recalled products shall be supervised and destroyed by the provincial drug supervision and management department of the place where they are located or other harmless treatment shall be taken in accordance with the law.
